Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1500 • ACR Convergence 2024
Work-Related Disability and Function in Systemic Lupus Erythematosus (SLE): Outcomes of an Exploratory Study from Different Canadian Centres
Behdin Nowrouzi-Kia¹, J. Antonio Avina-Zubieta², Mary Fox³, William Shaw⁴, Maggie Ho⁵, Qixuan Li⁵, Catherine Ivory⁶, Paul Fortin⁷, Stephanie Keeling⁸, Jennifer Reynolds⁹, Derek Haaland¹⁰, Janet Pope¹¹, Lily Lim¹², Patti Katz¹³, Murray Urowitz¹⁴, Laura Patricia Whittall Garcia⁵, Dafna Gladman¹⁵ and Zahi Touma¹, ¹University of Toronto, Toronto, ON, Canada, ²Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ³York University, Toronto, ON, Canada, ⁴University of Connecticut, School of Medicine, Farmington, CT, ⁵University Health Network, Toronto, ON, Canada, ⁶The Ottawa Hospital, Ottawa, ON, Canada, ⁷Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, ⁸University of Alberta, Edmonton, AB, Canada, ⁹UBC, North Vancouver, BC, Canada, ¹⁰The Waterside Clinic, Oro Medonte, ON, Canada, ¹¹University of Western Ontario, London, ON, Canada, ¹²University of Manitoba, Winnipeg, MB, Canada, ¹³UCSF, San Rafael, CA, ¹⁴Self employed, Toronto, ON, Canada, ¹⁵University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) has a significant and long-lasting impact on work outcomes, is a source of long-lasting work disability, and presents challenges with…
Abstract Number: 1516 • ACR Convergence 2024
Diagnostic Performance of Anti-ribosomal P Antibodies in Cerebrospinal Fluid of Neuropsychiatric Systemic Lupus Erythematosus with Diffuse Central Nervous System Manifestations. Experience in a Tertiary Center in Mexico
Marlon Sandino-Bermúdez¹, Erik Cimé-Aké², Jonathan Campos-Guzmán³, Eduardo Briones-García⁴, Emilio G. Lazarini², Carlos Núñez-Álvarez⁵ and Hilda Fragoso-Loyo², ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Distrito Federal, Mexico, ²Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Immunology and Rheumatology Department, Mexico City, Mexico, ³Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁴Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Immunology and Rheumatology Department., Ciudad de México, Distrito Federal, Mexico, ⁵Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, CDMX, Mexico, Mexico, Mexico
Background/Purpose: Diagnosing neuropsychiatric systemic lupus erythematosus (NPSLE) remains a challenge. The aim of this study was to evaluate the diagnostic performance of anti-ribosomal P antibodies…
Abstract Number: 1533 • ACR Convergence 2024
Imvotamab, a CD20-Targeted Bispecific IgM T Cell Engager, Effectively Depletes Low-Expressing CD20+ B Cells in Preclinical Models of Autoimmune Disease
Racquel Domingo-Gonzalez¹, Isabelle Baribaud², Shrishti Tyagi¹, Kevin Hart¹, Ryan Eberwine², Angus Sinclair¹, Albert Candia¹, Bruce Keyt¹, Merle Elloso², Maya Kotturi¹ and Mary Beth Harler¹, ¹IGM Biosciences, Inc., Mountain View, CA, ²IGM Biosciences, Inc., Doylestown, PA
Background/Purpose: B cell depletion therapy (BCDT) with conventional IgG mAbs has been employed for the treatment of autoimmune (AI) disease for ~20 years; however, many…
Abstract Number: 1553 • ACR Convergence 2024
Safety, Pharmacokinetics, Clinical Efficacy and Exploratory Biomarker Results from a Randomized, Double-Blind, Placebo-Controlled Phase 1b Study of Enpatoran in Active Systemic and Cutaneous Lupus Erythematosus (SLE/CLE)
Torsten Witte¹, Ruth Fernandez Ruiz², Nadezda Abramova³, Dominika Weinelt³, Flavie Moreau⁴, Lena Klopp-Schulze⁵, Jamie Shaw⁶, Deborah Denis⁷ and Joerg Wenzel⁸, ¹Dept of Immunology and Rheumatology, Hannover, Germany, ²Global Clinical Development, EMD Serono, Billerica, MA, ³Global Patient Safety, the healthcare business of Merck KGaA, Darmstadt, Germany, ⁴Global Biostatistics, EMD Serono, Billerica, MA, ⁵Quantitative Pharmacology, the healthcare business of Merck KGaA, Darmstadt, Germany, ⁶Companion Diagnostics and Biomarker Strategy, EMD Serono, Billerica, MA, ⁷EMD Serono, Rockland, MA, ⁸Department of Dermatology and Allergy, University Hospital of Bonn, Bonn, Germany
Background/Purpose: Enpatoran, a highly selective, potent and reversible dual toll-like receptor 7/8 (TLR7/8) inhibitor, targets key innate and adaptive immune processes involved in the pathogenesis…
Abstract Number: 1729 • ACR Convergence 2024
Prophylaxis Against Pneumocystis Jerovecii Pneumonia for Patients with Systemic Autoimmune Diseases: Analysis of the Veterans Affairs Database
Karolina Lungova¹, Katherine Sherman², Mahum Mirza¹, Rohan Mehta¹ and Michael Putman³, ¹Medical College of Wisconsin, Milwaukee, WI, ²Research Division, Zablocki Veterans Affairs, Milwaukee, ³The Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Pneumocystis jirovecii Pneumonia (PJP) is an opportunistic infection that may affect immunocompromised patients. PJP prophylaxis has been recommended for some autoimmune diseases but not others.…
Abstract Number: 1786 • ACR Convergence 2024
Select Immune Cell Dysregulation Identifies Clinically Quiescent Patients at Risk of Flare Who Stop Mycophenolate Mofetil While Continuing Hydroxychloroquine
Christian Wright¹, Rufei Lu², Catriona Wagner³, Carla Guthridge⁴, Susan Macwana¹, Eliza Chakravarty⁴, Tammy Utset⁵, Diane Kamen⁶, Gabriel Nicolas Contreras Martin⁷, William McCune⁸, Cynthia Aranow⁹, Kenneth Kalunian¹⁰, Elena Massarotti¹¹, Megan Clowse¹², Brad Rovin¹³, S. Sam Lim¹⁴, Vikas Majithia¹⁵, Richard Looney¹⁶, Maria Dall'Era¹⁷, Doruk Erkan¹⁸, Amit Saxena¹⁹, Nancy Olsen²⁰, Kichul Ko²¹, Ellen Goldmuntz²², William Barry²³, Ashley Pinckney²⁴, ALE06 Clinical Study Team⁴, Judith James⁴ and Joel Guthridge⁴, ¹Oklahoma Medical Research Foundation, Oklahoma City, ²University of California San Francisco, San Bruno, CA, ³Oklahoma Medical Research Foundation, Santa Cruz, CA, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵University of Chicago, Chicago, IL, ⁶Medical University of South Carolina, Charleston, SC, ⁷University of Miami, Key Biscayne, FL, ⁸U Michigan, Ann Arbor, MI, ⁹Feinstein Institutes for Medical Research, New York, NY, ¹⁰University of California San Diego, La Jolla, CA, ¹¹Brigham and Women's Hospital, Boston, MA, ¹²Duke University, Chapel Hill, NC, ¹³The Ohio State University, Columbus, OH, ¹⁴Emory University, Atlanta, GA, ¹⁵Mayo Clinic Florida, Jacksonville, FL, ¹⁶University of Rochester, Rochester, NY, ¹⁷UCSF, Corte Madera, CA, ¹⁸Hospital for Special Surgery, New York, NY, ¹⁹NYU School of Medicine, New York, NY, ²⁰Penn State University/Milton S Hershey, Hershey, PA, ²¹The University of Chicago, Chicago, IL, ²²NIAID/ NIH, Washington, DC, ²³Rho, Inc, Durham, NC, ²⁴Rho, St Louis Park, NC
Background/Purpose: Mycophenolate mofetil (MMF) is commonly used to treat major SLE manifestations; however, it is associated with significant toxicities. Thus, MMF withdrawal is desirable in…
Abstract Number: 1807 • ACR Convergence 2024
Identification of HDAC Inhibitor Targeting Type I Interferon and B-cell Abnormalities in Systemic Lupus Erythematosus
Takehiro Hirayama¹, Hyota Takamatsu² and Atsushi Kumanogoh³, ¹Osaka university, ibaraki city, Japan, ²National Hospital Organization Osaka Minami Medical Center, kawachinagano, Japan, ³Osaka University, Osaka, Japan
Background/Purpose: This study aimed to identify drugs that can inhibit both type I interferon (IFN-I) production and abnormal B-cell maturation and to elucidate the therapeutic…
Abstract Number: 1952 • ACR Convergence 2024
Interest in Clinical Trial Participation Among People with Lupus: Results from the Research Accelerated by You (RAY) Registry
Michael Fisher¹, Mimi Kim², Joan Merrill³, Safoah Agyemang¹ and Joy Buie¹, ¹Lupus Foundation of America, Washington, DC, ²Albert Einstein College of Medicine, New York, NY, ³Oklahoma Medical Research Foundation, Oklahoma City 73104, OK
Background/Purpose: With many treatments under study for SLE, a crisis in recruiting sufficient numbers of qualified patients for clinical trials has emerged. Willingness to consider…
Abstract Number: 2372 • ACR Convergence 2024
Incidence and Predictors of Recurrent Pericarditis in Systemic Lupus Erythematosus
Yoo Jin Kim¹, Jana Lovell¹, Alaa Diab¹, Laurence Magder², Daniel Goldman³, Michelle Petri³, Luigi Adamo¹ and Andrea Fava¹, ¹Johns Hopkins University, Baltimore, MD, ²University of Maryland, Baltimore, Baltimore, MD, ³Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Pericarditis is the most common cardiac manifestation of systemic lupus erythematosus (SLE). In the general population, pericarditis commonly recurs (~30%), likely due to immune-mediated…
Abstract Number: 2390 • ACR Convergence 2024
Anti-Sm Antibody Titers Vary During SLE Disease Course
Faye Megaris¹, Emily Wu² and Kyriakos Kirou³, ¹CUNY School of Medicine, Astoria, NY, ²Hospital for Special Surgery, Rochester, NY, ³Hospital for Special Surgery, New York, NY
Background/Purpose: Systemic Lupus Erythematosus (SLE) is characterized by positive antibodies to dsDNA and/or Sm which have high specificity for the disease. While anti-dsDNA titers are…
Abstract Number: 2409 • ACR Convergence 2024
Adherence to EULAR Recommendations and Sub Optimal Management of Systemic Lupus Erythematosus in a Network of Community-Based Rheumatology Practices in the United States
Jeffrey Curtis¹, Emily Holladay², Amy Mudano³, Emily Smitherman⁴, Fenglong xie⁵, Shanette G. Daigle⁶, Yujie Su³, Mawuena Binka⁷, Gelareh Atefi⁸, Rana Muhammad Qasim Khan⁹ and Tope Olufade¹⁰, ¹Illumination Health, Birmingham, AL, ²University of Alabama at Birmingham, Edmond, OK, ³Illumination Health, Hoover, AL, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵University of Alabama at Birmingham; Illumination Health, Birmingham, AL, ⁶Foundation for Advancing Science, Technology, Education, and Research, Birmingham, ⁷BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, ⁸AstraZeneca, Media, PA, ⁹BioPharmaceuticals Medical, AstraZeneca, Wilmington, ¹⁰AstraZeneca, Wilmington, DE
Background/Purpose: Despite new developments in systemic lupus erythematosus (SLE) treatment and treatment guidelines, the clinical management of SLE is often sub-optimal. We aimed to describe…
Abstract Number: 2425 • ACR Convergence 2024
Ianalumab Induced Durable Depletion of Circulating B Cell Subsets and Associated Changes in B Cell and Neutrophil Transcriptomic and Proteomic Profiles in Patients with Systemic Lupus Erythematosus: 52-Week Treatment Results from a Phase 2 Trial
Marianna Rowlands¹, Thomas Dörner², Diego Saldana Miranda³, Justin McMullen³, Aida Santos da Costa³, Ulrike Sommer³, Rainer Hillenbrand³, Andre Nogueira da Costa³, Claire Bonal³, Isabelle Isnardi³, Edward Khokhlovich¹ and Stephen J Oliver³, ¹Biomedical Research, Novartis, Cambridge, MA, ²Department of Medicine, Rheumatology and Clinical Immunology,Charite Universitätsmedizin Berlin, Germany and DRFZ, Berlin, Berlin, Germany, ³Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Ianalumab (VAY736), a B cell activating factor receptor (BAFFR) targeting mAb, depletes B cells via both antibody dependent cellular cytotoxicity and blockade of BAFF:BAFFR…
Abstract Number: 2546 • ACR Convergence 2024
Lipocalin-2 Drives Neuropsychiatric and Cutaneous SLE Through Regulation of Immune Cell Recruitment in Target Organs
Sayra Garcia¹, Elise Mike², Jinghang Zhang², Carla Cuda³ and Chaim Putterman⁴, ¹Albert Einstein College of Medicine, New York, NY, ²Albert Einstein, Bronx, NY, ³Northwestern University, Chicago, IL, ⁴Albert Einstein College of Medicine, Safed, Israel
Background/Purpose: About 20-40% of SLE patients develop neuropsychiatric SLE (NPSLE). NPSLE manifestations include impaired cognitive function and depression, both of which negatively impact the quality…
Abstract Number: 2605 • ACR Convergence 2024
Clarifying Misbeliefs & Resolving Decisional Conflicts About Hydroxychloroquine (HCQ) Through a Shared Decision-Making Tool (HCQ-SAFE©)
Shivani Garg¹, Jay Patel¹, Sancia Ferguson², Betty Chewning³, Shelby Gomez⁴, Jon keevil⁵, David Gazeley⁶, Patricia Tellez-Giron¹ and Christie Bartels⁷, ¹University of Wisconsin, School of Medicine and Public Health, Madison, Madison, WI, ²University of Wisconsin, Madison, Madison, WI, ³University of Wisconsin, School of Pharmacy, Madison, ⁴UW Health, Madison, ⁵N/A, Madison, ⁶Medical College of Wisconsin, Wauwatosa, WI, ⁷University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Treatment of lupus (or SLE) is complex, especially for young patients who are committed to take hydroxychloroquine (HCQ) lifelong, which carries some risk, albeit…
Abstract Number: 0093 • ACR Convergence 2024
Overexpression of Epidermal Ifnk Promotes Systemic CD8+ T Cell Maturation After UV-exposure
Benjamin Klein¹, Kelsey E. McNeely², Debbie Colesa², Yiqing Gao², Nguyen Thi Kim Nguyen², Johann Gudjonsson¹ and J. Michelle Kahlenberg¹, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan Michigan Medicine, Ann Arbor, MI
Background/Purpose: Skin involvement is the most common organ manifestation in systemic lupus erythematosus (SLE), and exacerbation of cutaneous lupus (CLE) can precede systemic disease flares.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].